≥99%
86168-78-7
3357.88 g/mol
Sermorelin
Sermorelin is a 29-amino acid synthetic peptide analog of GHRH(1-29) supplied for in-vitro receptor-activation assays, structural analysis, and analytical method development.
1 vial × $90 each
Add 3+ to unlock
volume pricing
Pay by Zelle or PayPal · no processing fees · ships once payment clears
Free US shipping on orders over $200, with tracking provided.
Third-party tested
Supplied to qualified labs and institutional buyers. Institutional use & buyer eligibility
Characteristics
| Property | Value |
|---|---|
| Molecular Formula | C₁₄₉H₂₄₆N₄₄O₄₂S |
| CAS Number | 86168-78-7 |
| Molar Mass | 3357.88 g/mol |
| Amino Acid Sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ |
| Synonyms | GHRH (1-29), GRF (1-29) NH₂, Sermorelin acetate |
| Physical Form | Lyophilized powder |
| Solubility | Soluble in water and aqueous laboratory solvent |
| Organoleptic Profile | White to off-white lyophilized powder; odorless |
| Storage Conditions | Store lyophilized at -20°C; reconstituted solution stable at 2-8°C for up to 14 days |
| Composition | Lyophilized sermorelin acetate |
How is Sermorelin Used in Research?
Sermorelin is a 29-amino acid synthetic peptide analog of GHRH(1-29), supplied as a lyophilized reference standard for in-vitro receptor-activation assays, structural analysis, and analytical method development. The 29-residue sequence corresponds to the N-terminal fragment of endogenous growth hormone-releasing hormone and is the minimal sequence that retains full binding activity at the GHRH receptor.
At the molecular level, sermorelin is studied as a GHRH-receptor ligand in in-vitro receptor-binding assays conducted in anterior pituitary somatotroph cell-culture systems. Binding activates the Gs-adenylyl cyclase-cAMP-PKA signaling cascade, which is tracked with standard biochemical readouts (cAMP accumulation assays, PKA-substrate phosphorylation panels). Supplied for laboratory characterization only. Not for use in any living organism.
Researchers use sermorelin as a reference compound in analytical method development — HPLC and mass-spectrometry identity assays, purity-profile characterization, and comparability work against newer GHRH analogs. In-vitro receptor-activation assays and structural analysis (circular dichroism, NMR conformational studies) represent the principal laboratory use cases for this research standard.
This product is supplied in a lyophilized form and requires reconstitution prior to laboratory handling. For research and laboratory use only. Not for human or veterinary consumption.
Areas of Study
In-Vitro Receptor-Activation Assays
Used as a GHRH-receptor reference ligand in cAMP accumulation assays on cultured somatotroph cell lines and recombinant GHRH-R expression systems.
Structural Analysis
Characterized by circular dichroism, NMR, and mass spectrometry to profile secondary-structure content and counter-ion composition.
Analytical Method Development
Applied as an identity and purity reference standard in HPLC assay development and comparability testing against newer GHRH analogs.
Receptor-Binding Studies
Employed in competitive binding assays to profile GHRH-R affinity of novel analogs and truncation mutants in cell-culture systems.
Reference Compound Use
Serves as a historical reference GHRH(1-29) standard for comparability and analytical characterization in laboratory workflows.
References
- [1]Walker RF. (2006). Sermorelin: a review of GHRH (1-29) as a research tool in growth hormone axis physiology. Clinical Interventions in Aging, 1(4), 307-308.
- [2]Gaylinn BD, Thorner MO. (2001). GHRH receptors, secretagogue receptors, and growth hormone secretion. Growth Hormone & IGF Research, 11(Suppl A), S35-S38.
- [3]Alba M, Fintini D, Bowers CY, et al. (2005). Effects of GHRH and GHRP-6, alone and in combination, on GH secretion in aged rats. Journal of Endocrinology, 185(3), 543-551.
Disclaimer: The information provided is for research reference only and does not constitute medical advice. Products are sold strictly for in-vitro research use.
Certificate of Analysis (COA)
Third-Party Verified Quality
Every batch of Sermorelinis independently tested by an A2LA-accredited (ISO 17025:2017) third-party laboratory using HPLC-UV/VIS for purity and measured quantity. Each COA carries the lab's signed report and a batch-specific lot number. We publish these results publicly so you can verify exactly what you're getting.
View Lab ResultsRelated Products
GLP3R
10mg – 60mg
Triple-agonist research peptide targeting GIP, GLP-1, and glucagon receptors in preclinical metabolic studies.
Ipamorelin 5mg + Mod GRF 1-29 (Blend)
5mg
Modified GRF 5mg, Ipamorelin 5mg (10mg Total Blend) {Modified GRF 5mg is the same substance also knows of CJC-1295 5mg (No DAC)} Modified GRF 5mg (or CJC-1295) causes the natural release of GH, but it does so by naturally stimulating the...
CJC-1295 no DAC (Mod GRF 1-29)
1 vial
CJC-1295 (no DAC) (Modified GRF) is a truncated peptide analogue of growth hormone releasing hormone (GHRH). First developed in the 1980s, research studies with modGRF have shown it to improve muscle repair and growth, accelerate wound...
CJC-1295 (no DAC), Ipamorelin 10mg (Blend)
10mg
CJC-1295 5mg (No DAC), Ipamorelin 5mg (10mg Total Peptide Blend) CJC-1295 causes the natural release of GH, but it does so by naturally stimulating the growth hormone releasing hormone receptor. Ipamorelin is one of the most selective...
Frequently Bought Together
Sermorelin
5mg
$90
GLP3R
10mg
$180
Ipamorelin 5mg + Mod GRF 1-29 (Blend)
5mg
$125
Bundle total
$395